Skip to main content

FDA panel votes against GLP-1 therapy from former diabetes unicorn Intarcia

By STAT News  
   September 22, 2023

An advisory panel to the FDA unanimously voted against a diabetes implant from Intarcia Therapeutics — a former biotech unicorn that faltered after the FDA twice rejected the implant.

Full story

Get the latest on healthcare leadership in your inbox.